Company Directory

Biodiversity-derived protein data and AI models for biological design

Basecamp Research is a London-based biotech company that collects biological samples from extreme environments across more than 26 countries, building a proprietary metagenomic database of over ten billion novel protein sequences from more than one million previously unrecorded species. This dataset trains large AI foundation models for designing novel proteins and genetic medicines. The company partners with pharmaceutical, biotechnology, and industrial organisations under ethically-sourced biodiversity agreements.

Transformative medicines for cystic fibrosis and serious genetic diseases

Vertex Pharmaceuticals is a global biopharmaceutical company with its European R&D headquarters at Milton Park, Oxfordshire, and its international commercial headquarters in London. The Oxford site conducts full-spectrum drug discovery encompassing human genetics, structural biology, and medicinal chemistry, and has been central to Vertex's development of approved therapies for cystic fibrosis. The company's broader pipeline addresses sickle cell disease, beta-thalassaemia, pain, and kidney disease, including gene-edited cell therapies.

Synthetic promoter platform for precision gene expression control

Chromatin Bioscience designs synthetic promoters and gene expression control systems for cell and gene therapy developers. Its platform uses bioinformatics to identify cell-type-selective regulatory elements from the human genome, which are assembled into novel synthetic promoters enabling precise, durable and targeted transgene expression. The company's promoters are integrated into partner programmes across oncology, nephrology and rare disease gene therapies, with a clinical-stage collaboration supporting an in vivo CAR-T candidate for multiple myeloma.

Next-generation programmable gene insertion platform technology

Gene Weaver is a preclinical-stage biotechnology company developing a programmable RNA-based gene insertion system. Its enzymatic system enables targeted insertion of large DNA payloads at virtually any genomic site without introducing double-strand breaks, addressing key limitations of existing tools including variable site integration and restricted payload size. The company received a $515,000 grant from the Bill and Melinda Gates Foundation in May 2025 to advance the technology toward gene therapy and affordable protein therapeutic manufacturing applications.

AI-driven intron technology to enhance transgene expression

ExpressionEdits is a biotechnology company developing computational tools to improve protein expression from artificial gene constructs. Its Genetic Syntax Engine uses machine learning and biological data to predict optimal intron insertion patterns within transgenes, increasing protein production levels in mammalian systems. The platform has applications across gene therapy, biologics development and recombinant protein manufacturing. The company is a spin-out from the University of Cambridge and has a collaboration with Boehringer Ingelheim.

Enzymatic synthetic DNA manufacture for gene therapy and molecular biology

NunaBio is a specialist DNA synthesis company developing a cell-free enzymatic platform for scalable production of synthetic DNA, including long oligonucleotides, whole genes and DNA fragments. Its technology avoids the plasmid and primer-dependent steps that constrain conventional phosphoramidite chemistry, enabling higher accuracy and length at reduced cost. Applications span gene therapy, T cell engineering, viral vector synthesis, mRNA therapeutics, diagnostics and DNA data storage.

BBSRC-funded national institute for animal biosciences research

The Roslin Institute is a BBSRC-funded national institute for animal biosciences research, part of the University of Edinburgh's Royal (Dick) School of Veterinary Studies. Research is organised around three challenge areas: sustainable farmed animal production, infectious disease detection and prevention, and translational animal and human health. The Institute has a strong track record in translational spinout activity, including RoslinCT and Roslin Technologies, and has pioneered gene editing applications in livestock

Gene editing platform for disease-resistant, climate-resilient tropical crops

Tropic Biosciences is an agricultural biotechnology company developing gene-edited varieties of tropical crops, including banana, coffee, and rice, with a focus on disease resistance, climate resilience, and yield improvement. Its proprietary platform combines gene editing with RNA interference to redirect a plant's natural silencing mechanisms without introducing foreign DNA, enabling non-GMO classification in several markets. The platform is licensed to major agricultural companies including BASF, Corteva, and Syngenta for trait development across additional crop species.

National facility for mouse genetics and preclinical disease modelling

The Mary Lyon Centre at MRC Harwell is the UK's national centre for mouse genetics, providing mouse model generation, phenotyping, cryopreservation, and archiving services to academic and industry researchers worldwide. The Centre offers genome engineering using CRISPR and other techniques to create genetically altered mouse models of human disease, and operates the UK National Mouse Archive. It serves as the central hub of the MRC National Mouse Genetics Network and delivers specialist training.

Proprietary gene editing tools and strain development services

Forge Genetics is a contract research organisation developing and applying a proprietary gene-editing platform as an alternative to CRISPR-based approaches. The company provides strain development, specialised fermentation including gas fermentation, and metabolite analytics services for pharmaceutical and industrial clients. The platform has been demonstrated across multiple bacterial species including Clostridia and Escherichia, and is licensed to industry partners for use in their own programmes.

Exosome-delivered gene editing therapies for neurodegenerative diseases

Evox Therapeutics is a biotechnology company developing exosome-based gene editing therapies for rare, genetically driven neurodegenerative diseases. Its proprietary platform uses engineered exosomes to deliver CRISPR-based gene editors across the blood-brain barrier, enabling targeted genetic intervention in the central nervous system. Lead programmes target the MSH3 gene in Huntington's disease and the ATXN2 gene in amyotrophic lateral sclerosis and spinocerebellar ataxia type 2, with additional programmes in Rett syndrome.

Automated single-cell isolation and cloning instruments for cell biology

Iota Sciences is a developer of automated single-cell handling instruments and cell-line engineering services. The company's platform automates single-cell isolation and cloning in nanolitre volumes, supporting monoclonal cell line development with integrated viability monitoring and documentation. GRID Technology provides a microfluidic alternative to standard microtitre plates for cell culture workflows. Services include bespoke genome-engineering of induced pluripotent stem cell lines for researchers requiring precisely edited cell models.